These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29113203)

  • 21. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
    Li GY; Duan JF; Li WJ; Liu T
    J Cancer Res Ther; 2016; 12(2):782-6. PubMed ID: 27461651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
    Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
    J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism.
    Mobaraki S; Nissen PH; Donskov F; Wozniak A; Van Herck Y; Coosemans L; van Nieuwenhuyse T; Lambrechts D; Bechter O; Baldewijns M; Roussel E; Laenen A; Beuselinck B
    Clin Genitourin Cancer; 2024 Oct; 22(5):102180. PubMed ID: 39155162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual Irinotecan Therapy Under the Guidance of Pre-Treated
    Lv H; Nie C; He Y; Chen B; Liu Y; Zhang J; Chen X
    Technol Cancer Res Treat; 2024; 23():15330338241236658. PubMed ID: 38497131
    [No Abstract]   [Full Text] [Related]  

  • 26. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.
    Takano M; Yamamoto K; Tabata T; Minegishi Y; Yokoyama T; Hirata E; Ikeda T; Shimada M; Yamada K; Morita S; Ando Y; Hirata K; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):115-24. PubMed ID: 26862009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
    Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
    Tagawa K; Maruo Y; Mimura Y; Ikushiro S
    Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
    Atasilp C; Biswas M; Jinda P; Nuntharadthanaphong N; Rachanakul J; Hongkaew Y; Vanwong N; Saokaew S; Sukasem C
    Clin Transl Sci; 2022 Jul; 15(7):1613-1633. PubMed ID: 35506159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
    Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
    Yang Y; Zhou M; Hu M; Cui Y; Zhong Q; Liang L; Huang F
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e479-e489. PubMed ID: 29932297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy.
    Harada T; Saito H; Karino F; Isaka T; Murakami S; Kondo T; Oshita F; Miyagi Y; Yamada K
    Mol Clin Oncol; 2014 Sep; 2(5):737-743. PubMed ID: 25054039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between
    Bai Y; Wu HW; Ma X; Liu Y; Zhang YH
    Onco Targets Ther; 2017; 10():3071-3081. PubMed ID: 28790841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Anai S; Iwama E; Yoneshima Y; Otsubo K; Tanaka K; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Dec; 126():156-161. PubMed ID: 30527181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [UGT1A1 Genotyping for Proper Use of Irinotecan].
    Matsuoka A; Ando Y
    Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.